Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Fuchs

Procedural Dermatology Falls Church, VA Medical Doctor

NPI 1124261177 CMS profile 278231

6565 Arlington Blvd Ste 102, Falls Church, VA 22042

Open in the dashboard

General payments

$375,712

1,541 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Fuchs of Falls Church, VA is reported in the CMS Open Payments database as having received $375,712 across 1,541 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $83,095 195
2024 General $59,574 217
2023 General $100,204 263
2022 General $61,800 229
2021 General $14,631 200
2020 General $22,930 166
2019 General $33,477 271

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Fuchs
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Aaron Fuchs were reported at $83,095. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Aaron Fuchs Procedural Dermatology median Middle half National median
2019 $33,477 $454 $152–$1,260 $163
2020 $22,930 $243 $90–$835 $114
2021 $14,631 $337 $102–$1,128 $132
2022 $61,800 $443 $119–$1,654 $149
2023 $100,204 $583 $137–$1,838 $160
2024 $59,574 $611 $132–$1,835 $164
2025 $83,095 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Incyte Corporation $67,558 113 payments
  2. Lilly USA, LLC $65,232 110 payments
  3. Dermavant Sciences, Inc. $64,754 79 payments
  4. Pfizer Inc. $60,375 128 payments
  5. Galderma Laboratories, L.P. $31,550 75 payments
  6. Novartis Pharmaceuticals Corporation $28,934 76 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $15,390 69 payments
  8. UCB, Inc. $8,478 51 payments
  9. Journey Medical Corporation $5,474 64 payments
  10. Genzyme Corporation $4,892 51 payments
  11. Other $23,075 725 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $288,185 156 payments
  2. Consulting Fee $33,017 20 payments
  3. Food and Beverage $28,323 1,255 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $12,160 9 payments
  5. Travel and Lodging $10,032 93 payments
  6. Honoraria $3,600 1 payment
  7. Education $395 7 payments
Products named General payments · program years 2019–2025
  1. VTAMA $68,544 82 payments
  2. OPZELURA $65,838 112 payments
  3. CIBINQO $48,009 67 payments
  4. NEMLUVIO $30,901 28 payments
  5. TALTZ $24,410 42 payments
  6. EBGLYSS $23,970 47 payments
  7. COSENTYX Immunology $15,709 40 payments
  8. DUOBRII $15,035 43 payments
  9. COSENTYX Dermatology $13,010 28 payments
  10. EUCRISA $12,845 87 payments
  11. Other $34,415 1,435 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,642

Median for Dermatology: 534

Drug cost

$988,582

Median for Dermatology: $67,151

Branded share of claims

26.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 111 $427,344
Tremfya Guselkumab Brand 15 $202,981
Humira Pen Adalimumab Brand 13 $90,734
Humira(Cf) Pen Adalimumab Brand 13 $88,525
Dupixent Syringe Dupilumab Brand 13 $57,382
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 39 $26,787
Jublia Efinaconazole Brand 16 $22,680
Pimecrolimus Generic 42 $10,467
Fluocinonide Generic 206 $9,974
Clobetasol Propionate Generic 116 $7,294

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$606,637

Medicare's payments for the services billed

Medicare patients

2,312

Average age 76

Services billed

12,109

949 women, 1,363 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 41%
Ischemic heart disease 22%
Cancer 16%
Diabetes 15%
Atrial fibrillation 15%
Chronic kidney disease 15%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
$25,839 — —
CIBINQO
$6,598 — —
VTAMA
$5,367 — —
TALTZ
$4,311 — —
DUPIXENT
$690 124 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,541 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record